Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2006
This study consists of a 2-week placebo-controlled double-blind inter-group efficacy study in moderate to severe refractory ulcerative colitis (UC) patients followed by a maximum of 12-week open-label efficacy and safety study in responders.
Epistemonikos ID: 5c3f2eb618270cd55f357e28dfb06db7c14f31a5
First added on: Mar 23, 2022